CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MAP Pharmaceuticals Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MAP Pharmaceuticals Inc.
Suite 200, 2400 Bayshore Parkway
Phone: (650) 386-3100p:650 386-3100 MOUNTAIN VIEW, CA  94043  United States Ticker: MAPPMAPP

This company ceased filing statements with the SEC on 3/11/2013.
This company is no longer actively traded on any major stock exchange.

Business Summary
MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer Timothy S.Nelson 48 3/1/2013 4/1/2005
Chief Financial Officer, Senior Vice President Christopher Y.Chai 45 1/1/2011 9/29/2006
Senior Vice President, General Counsel, Secretary Charlene A.Friedman 54 1/1/2011 7/26/2007
7 additional Officers and Directors records available in full report.

Business Names
Business Name
MAP Pharmaceuticals Inc.
MAP Pharmaceuticals, Inc.
MAPP

General Information
Number of Employees: 121 (As of 9/30/2012)
Outstanding Shares: 35,287,096 (As of 10/31/2012)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 200507047
Fax Number: (650) 386-3101


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023